<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.webmd.com/multiple-sclerosis/rrms-20/monthly-rms-treatment');</script>

        <script> var body_html = '<body> <section > <div ><header > <a >Skip to content</a> <div > <div > <a >Check Your Symptoms</a> <a >Find a Doctor</a> </div> <div > <div > <a >Sign In</a> <a >Sign Up</a> Subscribe </div> <div > <div > <ul > <li >My ProfileWelcome </li> <li > <ul > <li>My Tools</li> <li>My WebMD Pages</li> <li><a >My Account</a></li> <li><a >Sign Out</a></li> </ul> </li> </ul> </div> </div> </div> </div>  </header> </div> </section> <div > <section > <div ><section > <h6 > Life With Relapsing-Remitting Multiple Sclerosis </h6> </section></div> <div ><div > <div > <div >Sponsor content from</div> </div> </div> </div> <div ><header ><h1>The Challenges of Relapsing Multiple Sclerosis (MS) Can Add Up</h1></header></div> </section> <section > <div > <div > <div > <div >WHEN THEY DO,IT MAY BE TIME FOR A CHANGE.</div> </div> <div > <p>From experiencing relapses, to worrying about what may come next, the challenges of living with relapsing MS can really add up.</p> <p>When they do, it may be time to look into a relapsing MS treatment, like KESIMPTA<sup>®</sup> (ofatumumab).</p> <p >Sign up to get more details on KESIMPTA:</p> <ul> <li>Find out how it stacks up against another relapsing MS treatment*</li> <li>Learn about potential side effects</li> <li>See how this once-monthly, at-home injection could fit into your schedule<sup>†</sup></li> </ul> <div > <p >IMPORTANT:</p> <p >WebMD and Novartis Pharmaceuticals Corporation respect your privacy choices. By completing the form below you will transfer your information to Novartis Pharmaceuticals Corporation and its designated parties in order to fulfill your request. Novartis Pharmaceuticals Corporation and its designated parties will use your information as outlined in the Novartis Pharmaceuticals Corporation <a >Privacy Policy</a>. Entry of the below information indicates your agreement with the <a >Terms of Use</a>.</p> <div > <div > <h2>Thanks for signing up!</h2> <h3>Stay tuned for more KESIMPTA information delivered right to your inbox. Check your spam folder just in case!</h3> <h3>Want to learn more? Visit <a >KESIMPTA.com</a>.</h3> </div> </div> </div> <div > <p>RMS=relapsing multiple sclerosis.</p> <p >*In 2 studies vs teriflunomide.</p> <p ><sup>†</sup>After 3 weekly starter doses.</p> </div> </div> </div> </div> <div ><div > <div > <div > <h4 >Indication</h4> <p >What is KESIMPTA (ofatumumab) injection?</p> <p >KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.</p> <p >It is not known if KESIMPTA is safe or effective in children.</p> <h4 >Important Safety Information</h4> <p >Who should not take KESIMPTA?</p> <p >Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.</p> <p >What is the most important information I should know about KESIMPTA?</p> <p >KESIMPTA can cause serious side effects such as:</p> <ul> <li>Infections. Serious infections can happen during treatment with KESIMPTA. If you have an active infection, your healthcare provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.</li> <li>HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.</li> <li>Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.</li> <li >Weakened immune system. KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.</li> </ul> <p >Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:</p> <ul> <li>Have or think you have an infection including HBV or PML.</li> <li>Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.</li> <li>Have had a recent vaccination or are scheduled to receive any vaccinations. <ul> <li>You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.</li> <li>Whenever possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with KESIMPTA.</li> <li>Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.</li> </ul> </li> <li>Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.</li> <li >Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.</li> </ul> <p >Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p> <p >How should I use KESIMPTA?</p> <p >See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.</p> <ul> <li>Use KESIMPTA exactly as your HCP tells you to use it.</li> <li>Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.</li> <li >Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.</li> </ul> <p >KESIMPTA may cause serious side effects including:</p> <ul> <li>Injection-related reactions. Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. Talk with your HCP if you have any of these signs and symptoms: <ul> <li>at or near the injection site: redness of the skin, swelling, itching, and pain or</li> <li>that may happen when certain substances are released in your body: fever, headache, pain in the muscles, chills, and tiredness.</li> </ul> </li> <li >Low immunoglobulins. KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.</li> </ul> <p >The most common side effects of KESIMPTA include:</p> <ul> <li>Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.</li> <li >Headache.</li> </ul> <p >You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.</p> <p >Please see full Prescribing Information including Medication Guide.</p> <p >KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.</p> </div> </div></div><div > <ul> <li> <a >Prescribing Information |</a> </li> <li> <a >Medication Guide</a> </li> </ul> </div></div> <div ><div > <p >Copyright © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.</p> <p >8/21 135196</p> <p>WebMD does not endorse any specific product, service, or treatment.</p> </div></div> </section> <section > <div ><h4 >From WebMD</h4> <h3 >More on Multiple Sclerosis</h3> </div> <div ><div > <div > <h2>Health Solutions From Our Sponsors</h2> </div> <div > <ul> <li> Penis Curved When Erect? </li> <li> <a >Could I have CAD?</a> </li> <li> <a >Treat Bent Fingers</a> </li> <li> <a >Treat HR+, HER2- MBC</a> </li> <li> <a >Tired of Dandruff?</a> </li> <li> <a >Benefits of CBD</a> </li> <li> <a >Rethink MS Treatment</a> </li> <li> <a >AFib-Related Strokes</a> </li> <li> <a >Risk of a Future DVT/PE</a> </li> <li> <a >Is My Penis Normal?</a> </li> <li> <a >Relapsing MS Options</a> </li> <li> <a >Liver Transplants Save Lives</a> </li> <li> <a >Finance Plastic Surgery</a> </li> <li> <a >Bent Finger Causes</a> </li> <li> <a >Living With Psoriasis?</a> </li> <li> <a >Missing Teeth?</a> </li> </ul> </div> </div></div> </section> </div> <section > <div ><div > <div > <div > <p>Find WebMD on:</p> <ul > <li> <a >Facebook</a> </li> <li> <a >Twitter</a> </li> <li> <a >Pintrest</a> </li> </ul> </div> <div > <a >AdChoices</a> <a >AdChoices</a> </div> <div > <ul> <li> <a >About WebMD</a> </li> <li> <a >Advertise With Us</a> </li> <li> <a >Terms of Use</a> </li> <li> <a >Privacy Policy</a> </li> <li> <a >Cookie Policy</a> </li> <li> <a >Editorial Policy</a> </li> <li> <a >Contact Us</a> </li> </ul> </div> <div > <p>©2005-2019 WebMD LLC. All rights reserved.</p> <p >WebMD does not provide medical advice, diagnosis or treatment. <a >See additional information.</a></p> </div> </div> </div> <div > <div > <a > Show More </a> </div> <div > <div ><div > <div > <h4 >Indication</h4> <p >What is KESIMPTA (ofatumumab) injection?</p> <p >KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.</p> <p >It is not known if KESIMPTA is safe or effective in children.</p> <h4 >Important Safety Information</h4> <p >Who should not take KESIMPTA?</p> <p >Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.</p> <p >What is the most important information I should know about KESIMPTA?</p> <p >KESIMPTA can cause serious side effects such as:</p> <ul> <li>Infections. Serious infections can happen during treatment with KESIMPTA. If you have an active infection, your healthcare provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.</li> <li>HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.</li> <li>Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.</li> <li >Weakened immune system. KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.</li> </ul> <p >Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:</p> <ul> <li>Have or think you have an infection including HBV or PML.</li> <li>Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.</li> <li>Have had a recent vaccination or are scheduled to receive any vaccinations. <ul> <li>You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.</li> <li>Whenever possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with KESIMPTA.</li> <li>Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.</li> </ul> </li> <li>Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.</li> <li >Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.</li> </ul> <p >Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p> <p >How should I use KESIMPTA?</p> <p >See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.</p> <ul> <li>Use KESIMPTA exactly as your HCP tells you to use it.</li> <li>Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.</li> <li >Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.</li> </ul> <p >KESIMPTA may cause serious side effects including:</p> <ul> <li>Injection-related reactions. Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. Talk with your HCP if you have any of these signs and symptoms: <ul> <li>at or near the injection site: redness of the skin, swelling, itching, and pain or</li> <li>that may happen when certain substances are released in your body: fever, headache, pain in the muscles, chills, and tiredness.</li> </ul> </li> <li >Low immunoglobulins. KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.</li> </ul> <p >The most common side effects of KESIMPTA include:</p> <ul> <li>Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.</li> <li >Headache.</li> </ul> <p >You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a >www.fda.gov/medwatch</a>, or call 1-800-FDA-1088.</p> <p >Please see full <a >Prescribing Information</a> including <a >Medication Guide</a>.</p> <p >KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.</p> </div> </div></div> </div> </div> </div> </section> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, level: 1" node_number="1"> <section class="valid" valid="valid" title="valid: True, node: 2, level: 2" node_number="2"> <div class="valid" valid="valid" title="valid: True, node: 3, level: 3" node_number="3"><header class="valid" valid="valid" title="valid: True, node: 4, level: 4" node_number="4"> <a class="valid" valid="valid" title="valid: True, node: 5, level: 5" node_number="5">Skip to content</a> <div class="valid" valid="valid" title="valid: True, node: 6, level: 5" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, level: 6" node_number="7"> <a class="valid" valid="valid" title="valid: True, node: 8, level: 7" node_number="8">Check Your Symptoms</a> <a class="valid" valid="valid" title="valid: True, node: 9, level: 7" node_number="9">Find a Doctor</a> </div> <div class="valid" valid="valid" title="valid: True, node: 10, level: 6" node_number="10"> <div class="valid" valid="valid" title="valid: True, node: 11, level: 7" node_number="11"> <a class="valid" valid="valid" title="valid: True, node: 12, level: 8" node_number="12">Sign In</a> <a class="valid" valid="valid" title="valid: True, node: 13, level: 8" node_number="13">Sign Up</a> Subscribe </div> <div class="valid" valid="valid" title="valid: True, node: 14, level: 7" node_number="14"> <div class="valid" valid="valid" title="valid: True, node: 15, level: 8" node_number="15"> <ul class="valid" valid="valid" title="valid: True, node: 16, level: 9" node_number="16"> <li class="valid" valid="valid" title="valid: True, node: 17, level: 10" node_number="17">My ProfileWelcome </li> <li class="valid" valid="valid" title="valid: True, node: 18, level: 10" node_number="18"> <ul class="valid" valid="valid" title="valid: True, node: 19, level: 11" node_number="19"> <li class="valid" valid="valid" title="valid: True, node: 20, level: 12" node_number="20">My Tools</li> <li class="valid" valid="valid" title="valid: True, node: 21, level: 12" node_number="21">My WebMD Pages</li> <li class="valid" valid="valid" title="valid: True, node: 22, level: 12" node_number="22"><a class="valid" valid="valid" title="valid: True, node: 23, level: 13" node_number="23">My Account</a></li> <li class="valid" valid="valid" title="valid: True, node: 24, level: 12" node_number="24"><a class="valid" valid="valid" title="valid: True, node: 25, level: 13" node_number="25">Sign Out</a></li> </ul> </li> </ul> </div> </div> </div> </div>  </header> </div> </section> <div class="valid" valid="valid" title="valid: True, node: 26, level: 2" node_number="26"> <section class="valid" valid="valid" title="valid: True, node: 27, level: 3" node_number="27"> <div class="valid" valid="valid" title="valid: True, node: 28, level: 4" node_number="28"><section class="valid" valid="valid" title="valid: True, node: 29, level: 5" node_number="29"> <h6 class="valid" valid="valid" title="valid: True, node: 30, level: 6" node_number="30"> Life With Relapsing-Remitting Multiple Sclerosis </h6> </section></div> <div class="valid" valid="valid" title="valid: True, node: 31, level: 4" node_number="31"><div class="valid" valid="valid" title="valid: True, node: 32, level: 5" node_number="32"> <div class="valid" valid="valid" title="valid: True, node: 33, level: 6" node_number="33"> <div class="valid" valid="valid" title="valid: True, node: 34, level: 7" node_number="34">Sponsor content from</div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 35, level: 4" node_number="35"><header class="valid" valid="valid" title="valid: True, node: 36, level: 5" node_number="36"><h1 class="valid" valid="valid" title="valid: True, node: 37, level: 6" node_number="37">The Challenges of Relapsing Multiple Sclerosis (MS) Can Add Up</h1></header></div> </section> <section class="valid" valid="valid" title="valid: True, node: 38, level: 3" node_number="38"> <div class="valid" valid="valid" title="valid: True, node: 39, level: 4" node_number="39"> <div class="valid" valid="valid" title="valid: True, node: 40, level: 5" node_number="40"> <div class="valid" valid="valid" title="valid: True, node: 41, level: 6" node_number="41"> <div class="valid" valid="valid" title="valid: True, node: 42, level: 7" node_number="42">WHEN THEY DO,IT MAY BE TIME FOR A CHANGE.</div> </div> <div class="valid" valid="valid" title="valid: True, node: 43, level: 6" node_number="43"> <p class="valid" valid="valid" title="valid: True, node: 44, level: 7" node_number="44">From experiencing relapses, to worrying about what may come next, the challenges of living with relapsing MS can really add up.</p> <p class="valid" valid="valid" title="valid: True, node: 45, level: 7" node_number="45">When they do, it may be time to look into a relapsing MS treatment, like KESIMPTA<sup class="valid" valid="valid" title="valid: True, node: 46, level: 8" node_number="46">&#174;</sup> (ofatumumab).</p> <p class="valid" valid="valid" title="valid: True, node: 47, level: 7" node_number="47">Sign up to get more details on KESIMPTA:</p> <ul class="valid" valid="valid" title="valid: True, node: 48, level: 7" node_number="48"> <li class="valid" valid="valid" title="valid: True, node: 49, level: 8" node_number="49">Find out how it stacks up against another relapsing MS treatment*</li> <li class="valid" valid="valid" title="valid: True, node: 50, level: 8" node_number="50">Learn about potential side effects</li> <li class="valid" valid="valid" title="valid: True, node: 51, level: 8" node_number="51">See how this once-monthly, at-home injection could fit into your schedule<sup class="valid" valid="valid" title="valid: True, node: 52, level: 9" node_number="52">&#8224;</sup></li> </ul> <div class="valid" valid="valid" title="valid: True, node: 53, level: 7" node_number="53"> <p class="valid" valid="valid" title="valid: True, node: 54, level: 8" node_number="54">IMPORTANT:</p> <p class="valid" valid="valid" title="valid: True, node: 55, level: 8" node_number="55">WebMD and Novartis Pharmaceuticals Corporation respect your privacy choices. By completing the form below you will transfer your information to Novartis Pharmaceuticals Corporation and its designated parties in order to fulfill your request. Novartis Pharmaceuticals Corporation and its designated parties will use your information as outlined in the Novartis Pharmaceuticals Corporation <a class="valid" valid="valid" title="valid: True, node: 56, level: 9" node_number="56">Privacy Policy</a>. Entry of the below information indicates your agreement with the <a class="valid" valid="valid" title="valid: True, node: 57, level: 9" node_number="57">Terms of Use</a>.</p> <div class="valid" valid="valid" title="valid: True, node: 58, level: 8" node_number="58"> <div class="valid" valid="valid" title="valid: True, node: 59, level: 9" node_number="59"> <h2 class="valid" valid="valid" title="valid: True, node: 60, level: 10" node_number="60">Thanks for signing up!</h2> <h3 class="valid" valid="valid" title="valid: True, node: 61, level: 10" node_number="61">Stay tuned for more KESIMPTA information delivered right to your inbox. Check your spam folder just in case!</h3> <h3 class="valid" valid="valid" title="valid: True, node: 62, level: 10" node_number="62">Want to learn more? Visit <a class="valid" valid="valid" title="valid: True, node: 63, level: 11" node_number="63">KESIMPTA.com</a>.</h3> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 64, level: 7" node_number="64"> <p class="valid" valid="valid" title="valid: True, node: 65, level: 8" node_number="65">RMS=relapsing multiple sclerosis.</p> <p class="valid" valid="valid" title="valid: True, node: 66, level: 8" node_number="66">*In 2 studies vs teriflunomide.</p> <p class="valid" valid="valid" title="valid: True, node: 67, level: 8" node_number="67"><sup class="valid" valid="valid" title="valid: True, node: 68, level: 9" node_number="68">&#8224;</sup>After 3 weekly starter doses.</p> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 69, level: 4" node_number="69"><div class="valid" valid="valid" title="valid: True, node: 70, level: 5" node_number="70"> <div class="valid" valid="valid" title="valid: True, node: 71, level: 6" node_number="71"> <div class="valid" valid="valid" title="valid: True, node: 72, level: 7" node_number="72"> <h4 class="valid" valid="valid" title="valid: True, node: 73, level: 8" node_number="73">Indication</h4> <p class="valid" valid="valid" title="valid: True, node: 74, level: 8" node_number="74">What is KESIMPTA (ofatumumab) injection?</p> <p class="valid" valid="valid" title="valid: True, node: 75, level: 8" node_number="75">KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.</p> <p class="valid" valid="valid" title="valid: True, node: 76, level: 8" node_number="76">It is not known if KESIMPTA is safe or effective in children.</p> <h4 class="valid" valid="valid" title="valid: True, node: 77, level: 8" node_number="77">Important Safety Information</h4> <p class="valid" valid="valid" title="valid: True, node: 78, level: 8" node_number="78">Who should not take KESIMPTA?</p> <p class="valid" valid="valid" title="valid: True, node: 79, level: 8" node_number="79">Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.</p> <p class="valid" valid="valid" title="valid: True, node: 80, level: 8" node_number="80">What is the most important information I should know about KESIMPTA?</p> <p class="valid" valid="valid" title="valid: True, node: 81, level: 8" node_number="81">KESIMPTA can cause serious side effects such as:</p> <ul class="valid" valid="valid" title="valid: True, node: 82, level: 8" node_number="82"> <li class="valid" valid="valid" title="valid: True, node: 83, level: 9" node_number="83">Infections. Serious infections can happen during treatment with KESIMPTA. If you have an active infection, your healthcare provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.</li> <li class="valid" valid="valid" title="valid: True, node: 84, level: 9" node_number="84">HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.</li> <li class="valid" valid="valid" title="valid: True, node: 85, level: 9" node_number="85">Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.</li> <li class="valid" valid="valid" title="valid: True, node: 86, level: 9" node_number="86">Weakened immune system. KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 87, level: 8" node_number="87">Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:</p> <ul class="valid" valid="valid" title="valid: True, node: 88, level: 8" node_number="88"> <li class="valid" valid="valid" title="valid: True, node: 89, level: 9" node_number="89">Have or think you have an infection including HBV or PML.</li> <li class="valid" valid="valid" title="valid: True, node: 90, level: 9" node_number="90">Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.</li> <li class="valid" valid="valid" title="valid: True, node: 91, level: 9" node_number="91">Have had a recent vaccination or are scheduled to receive any vaccinations. <ul class="valid" valid="valid" title="valid: True, node: 92, level: 10" node_number="92"> <li class="valid" valid="valid" title="valid: True, node: 93, level: 11" node_number="93">You should receive any required &#8216;live&#8217; or &#8216;live-attenuated&#8217; vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive &#8216;live&#8217; or &#8216;live-attenuated&#8217; vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.</li> <li class="valid" valid="valid" title="valid: True, node: 94, level: 11" node_number="94">Whenever possible, you should receive any &#8216;non-live&#8217; vaccines at least 2 weeks before you start treatment with KESIMPTA.</li> <li class="valid" valid="valid" title="valid: True, node: 95, level: 11" node_number="95">Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.</li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 96, level: 9" node_number="96">Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.</li> <li class="valid" valid="valid" title="valid: True, node: 97, level: 9" node_number="97">Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 98, level: 8" node_number="98">Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p> <p class="valid" valid="valid" title="valid: True, node: 99, level: 8" node_number="99">How should I use KESIMPTA?</p> <p class="valid" valid="valid" title="valid: True, node: 100, level: 8" node_number="100">See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.</p> <ul class="valid" valid="valid" title="valid: True, node: 101, level: 8" node_number="101"> <li class="valid" valid="valid" title="valid: True, node: 102, level: 9" node_number="102">Use KESIMPTA exactly as your HCP tells you to use it.</li> <li class="valid" valid="valid" title="valid: True, node: 103, level: 9" node_number="103">Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.</li> <li class="valid" valid="valid" title="valid: True, node: 104, level: 9" node_number="104">Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 105, level: 8" node_number="105">KESIMPTA may cause serious side effects including:</p> <ul class="valid" valid="valid" title="valid: True, node: 106, level: 8" node_number="106"> <li class="valid" valid="valid" title="valid: True, node: 107, level: 9" node_number="107">Injection-related reactions. Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. Talk with your HCP if you have any of these signs and symptoms: <ul class="valid" valid="valid" title="valid: True, node: 108, level: 10" node_number="108"> <li class="valid" valid="valid" title="valid: True, node: 109, level: 11" node_number="109">at or near the injection site: redness of the skin, swelling, itching, and pain or</li> <li class="valid" valid="valid" title="valid: True, node: 110, level: 11" node_number="110">that may happen when certain substances are released in your body: fever, headache, pain in the muscles, chills, and tiredness.</li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 111, level: 9" node_number="111">Low immunoglobulins. KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 112, level: 8" node_number="112">The most common side effects of KESIMPTA include:</p> <ul class="valid" valid="valid" title="valid: True, node: 113, level: 8" node_number="113"> <li class="valid" valid="valid" title="valid: True, node: 114, level: 9" node_number="114">Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.</li> <li class="valid" valid="valid" title="valid: True, node: 115, level: 9" node_number="115">Headache.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 116, level: 8" node_number="116">You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.</p> <p class="valid" valid="valid" title="valid: True, node: 117, level: 8" node_number="117">Please see full Prescribing Information including Medication Guide.</p> <p class="valid" valid="valid" title="valid: True, node: 118, level: 8" node_number="118">KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.</p> </div> </div></div><div class="valid" valid="valid" title="valid: True, node: 119, level: 5" node_number="119"> <ul class="valid" valid="valid" title="valid: True, node: 120, level: 6" node_number="120"> <li class="valid" valid="valid" title="valid: True, node: 121, level: 7" node_number="121"> <a class="valid" valid="valid" title="valid: True, node: 122, level: 8" node_number="122">Prescribing Information |</a> </li> <li class="valid" valid="valid" title="valid: True, node: 123, level: 7" node_number="123"> <a class="valid" valid="valid" title="valid: True, node: 124, level: 8" node_number="124">Medication Guide</a> </li> </ul> </div></div> <div class="valid" valid="valid" title="valid: True, node: 125, level: 4" node_number="125"><div class="valid" valid="valid" title="valid: True, node: 126, level: 5" node_number="126"> <p class="valid" valid="valid" title="valid: True, node: 127, level: 6" node_number="127">Copyright &#169; 2021 Novartis Pharmaceuticals Corporation. All rights reserved.</p> <p class="valid" valid="valid" title="valid: True, node: 128, level: 6" node_number="128">8/21 135196</p> <p class="valid" valid="valid" title="valid: True, node: 129, level: 6" node_number="129">WebMD does not endorse any specific product, service, or treatment.</p> </div></div> </section> <section class="valid" valid="valid" title="valid: True, node: 130, level: 3" node_number="130"> <div class="valid" valid="valid" title="valid: True, node: 131, level: 4" node_number="131"><h4 class="valid" valid="valid" title="valid: True, node: 132, level: 5" node_number="132">From WebMD</h4> <h3 class="valid" valid="valid" title="valid: True, node: 133, level: 5" node_number="133">More on Multiple Sclerosis</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 134, level: 4" node_number="134"><div class="valid" valid="valid" title="valid: True, node: 135, level: 5" node_number="135"> <div class="valid" valid="valid" title="valid: True, node: 136, level: 6" node_number="136"> <h2 class="valid" valid="valid" title="valid: True, node: 137, level: 7" node_number="137">Health Solutions From Our Sponsors</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 138, level: 6" node_number="138"> <ul class="valid" valid="valid" title="valid: True, node: 139, level: 7" node_number="139"> <li class="valid" valid="valid" title="valid: True, node: 140, level: 8" node_number="140"> Penis Curved When Erect? </li> <li class="valid" valid="valid" title="valid: True, node: 141, level: 8" node_number="141"> <a class="valid" valid="valid" title="valid: True, node: 142, level: 9" node_number="142">Could I have CAD?</a> </li> <li class="valid" valid="valid" title="valid: True, node: 143, level: 8" node_number="143"> <a class="valid" valid="valid" title="valid: True, node: 144, level: 9" node_number="144">Treat Bent Fingers</a> </li> <li class="valid" valid="valid" title="valid: True, node: 145, level: 8" node_number="145"> <a class="valid" valid="valid" title="valid: True, node: 146, level: 9" node_number="146">Treat HR+, HER2- MBC</a> </li> <li class="valid" valid="valid" title="valid: True, node: 147, level: 8" node_number="147"> <a class="valid" valid="valid" title="valid: True, node: 148, level: 9" node_number="148">Tired of Dandruff?</a> </li> <li class="valid" valid="valid" title="valid: True, node: 149, level: 8" node_number="149"> <a class="valid" valid="valid" title="valid: True, node: 150, level: 9" node_number="150">Benefits of CBD</a> </li> <li class="valid" valid="valid" title="valid: True, node: 151, level: 8" node_number="151"> <a class="valid" valid="valid" title="valid: True, node: 152, level: 9" node_number="152">Rethink MS Treatment</a> </li> <li class="valid" valid="valid" title="valid: True, node: 153, level: 8" node_number="153"> <a class="valid" valid="valid" title="valid: True, node: 154, level: 9" node_number="154">AFib-Related Strokes</a> </li> <li class="valid" valid="valid" title="valid: True, node: 155, level: 8" node_number="155"> <a class="valid" valid="valid" title="valid: True, node: 156, level: 9" node_number="156">Risk of a Future DVT/PE</a> </li> <li class="valid" valid="valid" title="valid: True, node: 157, level: 8" node_number="157"> <a class="valid" valid="valid" title="valid: True, node: 158, level: 9" node_number="158">Is My Penis Normal?</a> </li> <li class="valid" valid="valid" title="valid: True, node: 159, level: 8" node_number="159"> <a class="valid" valid="valid" title="valid: True, node: 160, level: 9" node_number="160">Relapsing MS Options</a> </li> <li class="valid" valid="valid" title="valid: True, node: 161, level: 8" node_number="161"> <a class="valid" valid="valid" title="valid: True, node: 162, level: 9" node_number="162">Liver Transplants Save Lives</a> </li> <li class="valid" valid="valid" title="valid: True, node: 163, level: 8" node_number="163"> <a class="valid" valid="valid" title="valid: True, node: 164, level: 9" node_number="164">Finance Plastic Surgery</a> </li> <li class="valid" valid="valid" title="valid: True, node: 165, level: 8" node_number="165"> <a class="valid" valid="valid" title="valid: True, node: 166, level: 9" node_number="166">Bent Finger Causes</a> </li> <li class="valid" valid="valid" title="valid: True, node: 167, level: 8" node_number="167"> <a class="valid" valid="valid" title="valid: True, node: 168, level: 9" node_number="168">Living With Psoriasis?</a> </li> <li class="valid" valid="valid" title="valid: True, node: 169, level: 8" node_number="169"> <a class="valid" valid="valid" title="valid: True, node: 170, level: 9" node_number="170">Missing Teeth?</a> </li> </ul> </div> </div></div> </section> </div> <section class="valid" valid="valid" title="valid: True, node: 171, level: 2" node_number="171"> <div class="valid" valid="valid" title="valid: True, node: 172, level: 3" node_number="172"><div class="valid" valid="valid" title="valid: True, node: 173, level: 4" node_number="173"> <div class="valid" valid="valid" title="valid: True, node: 174, level: 5" node_number="174"> <div class="valid" valid="valid" title="valid: True, node: 175, level: 6" node_number="175"> <p class="valid" valid="valid" title="valid: True, node: 176, level: 7" node_number="176">Find WebMD on:</p> <ul class="valid" valid="valid" title="valid: True, node: 177, level: 7" node_number="177"> <li class="valid" valid="valid" title="valid: True, node: 178, level: 8" node_number="178"> <a class="valid" valid="valid" title="valid: True, node: 179, level: 9" node_number="179">Facebook</a> </li> <li class="valid" valid="valid" title="valid: True, node: 180, level: 8" node_number="180"> <a class="valid" valid="valid" title="valid: True, node: 181, level: 9" node_number="181">Twitter</a> </li> <li class="valid" valid="valid" title="valid: True, node: 182, level: 8" node_number="182"> <a class="valid" valid="valid" title="valid: True, node: 183, level: 9" node_number="183">Pintrest</a> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 184, level: 6" node_number="184"> <a class="valid" valid="valid" title="valid: True, node: 185, level: 7" node_number="185">AdChoices</a> <a class="valid" valid="valid" title="valid: True, node: 186, level: 7" node_number="186">AdChoices</a> </div> <div class="valid" valid="valid" title="valid: True, node: 187, level: 6" node_number="187"> <ul class="valid" valid="valid" title="valid: True, node: 188, level: 7" node_number="188"> <li class="valid" valid="valid" title="valid: True, node: 189, level: 8" node_number="189"> <a class="valid" valid="valid" title="valid: True, node: 190, level: 9" node_number="190">About WebMD</a> </li> <li class="valid" valid="valid" title="valid: True, node: 191, level: 8" node_number="191"> <a class="valid" valid="valid" title="valid: True, node: 192, level: 9" node_number="192">Advertise With Us</a> </li> <li class="valid" valid="valid" title="valid: True, node: 193, level: 8" node_number="193"> <a class="valid" valid="valid" title="valid: True, node: 194, level: 9" node_number="194">Terms of Use</a> </li> <li class="valid" valid="valid" title="valid: True, node: 195, level: 8" node_number="195"> <a class="valid" valid="valid" title="valid: True, node: 196, level: 9" node_number="196">Privacy Policy</a> </li> <li class="valid" valid="valid" title="valid: True, node: 197, level: 8" node_number="197"> <a class="valid" valid="valid" title="valid: True, node: 198, level: 9" node_number="198">Cookie Policy</a> </li> <li class="valid" valid="valid" title="valid: True, node: 199, level: 8" node_number="199"> <a class="valid" valid="valid" title="valid: True, node: 200, level: 9" node_number="200">Editorial Policy</a> </li> <li class="valid" valid="valid" title="valid: True, node: 201, level: 8" node_number="201"> <a class="valid" valid="valid" title="valid: True, node: 202, level: 9" node_number="202">Contact Us</a> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 203, level: 6" node_number="203"> <p class="valid" valid="valid" title="valid: True, node: 204, level: 7" node_number="204">&#169;2005-2019 WebMD LLC. All rights reserved.</p> <p class="valid" valid="valid" title="valid: True, node: 205, level: 7" node_number="205">WebMD does not provide medical advice, diagnosis or treatment. <a class="valid" valid="valid" title="valid: True, node: 206, level: 8" node_number="206">See additional information.</a></p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 207, level: 4" node_number="207"> <div class="valid" valid="valid" title="valid: True, node: 208, level: 5" node_number="208"> <a class="valid" valid="valid" title="valid: True, node: 209, level: 6" node_number="209"> Show More </a> </div> <div class="valid" valid="valid" title="valid: True, node: 210, level: 5" node_number="210"> <div class="valid" valid="valid" title="valid: True, node: 211, level: 6" node_number="211"><div class="valid" valid="valid" title="valid: True, node: 212, level: 7" node_number="212"> <div class="valid" valid="valid" title="valid: True, node: 213, level: 8" node_number="213"> <h4 class="valid" valid="valid" title="valid: True, node: 214, level: 9" node_number="214">Indication</h4> <p class="valid" valid="valid" title="valid: True, node: 215, level: 9" node_number="215">What is KESIMPTA (ofatumumab) injection?</p> <p class="valid" valid="valid" title="valid: True, node: 216, level: 9" node_number="216">KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.</p> <p class="valid" valid="valid" title="valid: True, node: 217, level: 9" node_number="217">It is not known if KESIMPTA is safe or effective in children.</p> <h4 class="valid" valid="valid" title="valid: True, node: 218, level: 9" node_number="218">Important Safety Information</h4> <p class="valid" valid="valid" title="valid: True, node: 219, level: 9" node_number="219">Who should not take KESIMPTA?</p> <p class="valid" valid="valid" title="valid: True, node: 220, level: 9" node_number="220">Do NOT take KESIMPTA if you have active hepatitis B virus (HBV) infection.</p> <p class="valid" valid="valid" title="valid: True, node: 221, level: 9" node_number="221">What is the most important information I should know about KESIMPTA?</p> <p class="valid" valid="valid" title="valid: True, node: 222, level: 9" node_number="222">KESIMPTA can cause serious side effects such as:</p> <ul class="valid" valid="valid" title="valid: True, node: 223, level: 9" node_number="223"> <li class="valid" valid="valid" title="valid: True, node: 224, level: 10" node_number="224">Infections. Serious infections can happen during treatment with KESIMPTA. If you have an active infection, your healthcare provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.</li> <li class="valid" valid="valid" title="valid: True, node: 225, level: 10" node_number="225">HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.</li> <li class="valid" valid="valid" title="valid: True, node: 226, level: 10" node_number="226">Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.</li> <li class="valid" valid="valid" title="valid: True, node: 227, level: 10" node_number="227">Weakened immune system. KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 228, level: 9" node_number="228">Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:</p> <ul class="valid" valid="valid" title="valid: True, node: 229, level: 9" node_number="229"> <li class="valid" valid="valid" title="valid: True, node: 230, level: 10" node_number="230">Have or think you have an infection including HBV or PML.</li> <li class="valid" valid="valid" title="valid: True, node: 231, level: 10" node_number="231">Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.</li> <li class="valid" valid="valid" title="valid: True, node: 232, level: 10" node_number="232">Have had a recent vaccination or are scheduled to receive any vaccinations. <ul class="valid" valid="valid" title="valid: True, node: 233, level: 11" node_number="233"> <li class="valid" valid="valid" title="valid: True, node: 234, level: 12" node_number="234">You should receive any required &#8216;live&#8217; or &#8216;live-attenuated&#8217; vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive &#8216;live&#8217; or &#8216;live-attenuated&#8217; vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.</li> <li class="valid" valid="valid" title="valid: True, node: 235, level: 12" node_number="235">Whenever possible, you should receive any &#8216;non-live&#8217; vaccines at least 2 weeks before you start treatment with KESIMPTA.</li> <li class="valid" valid="valid" title="valid: True, node: 236, level: 12" node_number="236">Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.</li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 237, level: 10" node_number="237">Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.</li> <li class="valid" valid="valid" title="valid: True, node: 238, level: 10" node_number="238">Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 239, level: 9" node_number="239">Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p> <p class="valid" valid="valid" title="valid: True, node: 240, level: 9" node_number="240">How should I use KESIMPTA?</p> <p class="valid" valid="valid" title="valid: True, node: 241, level: 9" node_number="241">See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.</p> <ul class="valid" valid="valid" title="valid: True, node: 242, level: 9" node_number="242"> <li class="valid" valid="valid" title="valid: True, node: 243, level: 10" node_number="243">Use KESIMPTA exactly as your HCP tells you to use it.</li> <li class="valid" valid="valid" title="valid: True, node: 244, level: 10" node_number="244">Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.</li> <li class="valid" valid="valid" title="valid: True, node: 245, level: 10" node_number="245">Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 246, level: 9" node_number="246">KESIMPTA may cause serious side effects including:</p> <ul class="valid" valid="valid" title="valid: True, node: 247, level: 9" node_number="247"> <li class="valid" valid="valid" title="valid: True, node: 248, level: 10" node_number="248">Injection-related reactions. Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. Talk with your HCP if you have any of these signs and symptoms: <ul class="valid" valid="valid" title="valid: True, node: 249, level: 11" node_number="249"> <li class="valid" valid="valid" title="valid: True, node: 250, level: 12" node_number="250">at or near the injection site: redness of the skin, swelling, itching, and pain or</li> <li class="valid" valid="valid" title="valid: True, node: 251, level: 12" node_number="251">that may happen when certain substances are released in your body: fever, headache, pain in the muscles, chills, and tiredness.</li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 252, level: 10" node_number="252">Low immunoglobulins. KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 253, level: 9" node_number="253">The most common side effects of KESIMPTA include:</p> <ul class="valid" valid="valid" title="valid: True, node: 254, level: 9" node_number="254"> <li class="valid" valid="valid" title="valid: True, node: 255, level: 10" node_number="255">Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.</li> <li class="valid" valid="valid" title="valid: True, node: 256, level: 10" node_number="256">Headache.</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 257, level: 9" node_number="257">You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a class="valid" valid="valid" title="valid: True, node: 258, level: 10" node_number="258">www.fda.gov/medwatch</a>, or call 1-800-FDA-1088.</p> <p class="valid" valid="valid" title="valid: True, node: 259, level: 9" node_number="259">Please see full <a class="valid" valid="valid" title="valid: True, node: 260, level: 10" node_number="260">Prescribing Information</a> including <a class="valid" valid="valid" title="valid: True, node: 261, level: 10" node_number="261">Medication Guide</a>.</p> <p class="valid" valid="valid" title="valid: True, node: 262, level: 9" node_number="262">KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.</p> </div> </div></div> </div> </div> </div> </section> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>